Source: Annual Congress 2002 - Interstitial lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Rottoli, E. Bargagli, F. A. Cimmino, M. Galeazzi, R. Marcolongo (Siena, Italy). Infliximab treatment in patients with interstitial lung disease and rheumatoid arthritis. Eur Respir J 2002; 20: Suppl. 38, 3675

Member's Comments

No comment yet.

Related content which might interest you: Infliximab therapy in interstitial lung disease associated with rheumatoid arthritis Source: Annual Congress 2004 - Fibrosing lung diseases Year: 2004 Rituximab improves interstitial lung disease in rheumatoid arthritis patients Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis Source: Eur Respir J 2004; 24 : 708 Year: 2004 Interstitial lung disease in patients with rheumatoid arthritis Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases Year: 2008 Methotrexate and rheumatoid arthritis associated interstitial lung disease Source: Eur Respir J, 57 (2) 2000337; 10.1183/13993003.00337-2020 Year: 2021 Effect of tocilizumab on interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) Source: Virtual Congress 2020 – Non-idiopathic pulmonary fibrosis interstitial lung diseases: mechanisms, diagnosis and treatment Year: 2020 The effect of Rituximab treatment on progression of Rheumatoid arthritis-associated interstitial lung disease Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management Year: 2018 Mortality and clinical features in rheumatoid arthritis and interstitial lung disease Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Duration of rheumatoid arthritis and the risk of developing interstitial lung disease Source: ERJ Open Res, 7 (1) 00633-2020; 10.1183/23120541.00633-2020 Year: 2021 Predicting outcomes in rheumatoid arthritis related interstitial lung disease Source: Eur Respir J, 53 (1) 1800869; 10.1183/13993003.00869-2018 Year: 2019 Risk factors of interstitial lung diseases in patients with rheumatoid arthritis. Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Pulmonary involvement in patients with rheumatoid arthritis Source: Eur Respir J 2006; 28: Suppl. 50, 381s Year: 2006 The lung in rheumatoid arthritis: drugs versus underlying disease Source: Annual Congress 2009 - Lung disease in rheumatoid arthritis treated with tumour necrosis factor inhibitors: a pulmonary perspective Year: 2009 RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients Source: Eur Respir J 2014; 44: 1082-1085 Year: 2014 Pulmonary manifestations in patients with rheumatoid arthritis Source: Eur Respir J 2006; 28: Suppl. 50, 100s Year: 2006 Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease Source: Eur Respir J 2016; 47: 588-596 Year: 2016 Cavitary nodules in rheumatoid arthritis patients and their prognosis Source: International Congress 2018 – Sarcoidosis, interstitial lung diseases and various clinical problems Year: 2018 Pulmonary disease associated with rheumatoid arthritis Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease Source: Eur Respir J 2010; 35: 1206-1208 Year: 2010 Pulmonary non-Hodgkin‘s lymphoma developed during long-term methotrexate therapy for rheumatoid arthritis Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours Year: 2009